Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism
(PE), is a common post-operative complication. The effectiveness of fondaparinux compared
with other injectable anticoagulants in VTE following major orthopedic and abdominal surgery
has been evaluated in database studies; however, the effectiveness of injectable
anticoagulant medications following cancer-related surgeries in the practice setting has not
been as well documented.
The objective of this study is to analyze patient records from a national hospital database
and compare the outcomes and costs between four types of injectable anticoagulant medications
that were prescribed for the prevention of VTE following cancer-related surgery. This
analysis will assess and quantify the outcomes, resource utilization, and cost of care for
patients receiving fondaparinux, enoxaparin, dalteparin or unfractionated heparin. The
outcomes of interest include the occurence of VTE, rates of major bleeds, medical resource
utilization, and total costs (medical plus pharmacy).
The source of data for this study is the Premier Perspective Database™. This hospital claims
database links de-identified inpatient medical, pharmacy, and billing data from more than 500
hospitals.
This study is a retrospective cohort study that uses propensity score matching to adjust for
the differences between the numbers of patients treated with each medication.